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Mahler and colleagues posed a question on the reliability of
the indirect immunofluorescence method using the HEp-2
cell line in their recent Arthritis Research and Therapy article
[1]. Products from three different companies showed
different staining patterns on the same anti-ribosomal P (anti-
Rib-P) in the pictures they revealed. In addition to the anti-
Rib-P that Mahler and colleagues mentioned, limitations of
the HEp-2 cell line in the detection of autoantibodies such as
anti-Ro have long been pointed out. The HEp-2000 cell line,
which was developed to overcome such limitations, did not
show any superior performance in the detection of anti-Rib-P
since it was a form of HEp-2 cell that was transfected with
cDNA encoding human Ro60. A human macrophage cell line
called the IT-1 cell line was first introduced at the American
College of Rheumatology meeting held in Minneapolis in
1994 [2], the same time as HEp-2000 was presented. IT-1
had been commercialized and passed inspection by the
Korea Food and Drug Administration in South Korea.
Currently, IT-1 is being used under the name of the
autoimmune target (AIT) test and it participates in the quality
control program run by the Korean Society of Laboratory
Medicine [3]. In 1999 and 2007, reports of antinuclear
antibody test using the IT-1 cell line on 208 and 588
systemic lupus erythematosus (SLE) patients, respectively,
showed a 100% positive rate that proved an exceptional
improvement in the test performance [4,5]. Furthermore, the
AIT test can indirectly help in the diagnosis of SLE using the
microtubule organizing center pattern (MTOC) that can only
be observed in the IT-1 cell line [4].
We investigated patients who were tested for anti-Rib-P
using a double immunodiffusion method from April 1995 to
March 2009. Anti-Rib-P was detected in 102 patients. AIT
tests showed all positive results in anti-Rib-P-positive
patients, and all patients showed a diffuse cytoplasmic
pattern with no exception (Table 1). Although there were
some differences according to other accompanying
fluorescent patterns, most of the patients (100 patients,
98%) showed a high titer of greater than 1:640 (Table 1).
Opinions about including anti-Rib-P in the diagnostic criteria
of SLE have been recently suggested, like Mahler and
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Table 1
Immunofluorescence patterns and titers of the autoimmune target test in anti-ribosomal P-positive patients
Titer of diffuse cytoplasmic pattern
Immunofluorescence patterns 1:320 1:640 1:1,280 ≥1:2,560 Total patients
Diffuse cytoplasmic only 0 1 7 15 23
Diffuse cytoplasmic + nucleolar 0 4 4 20 28
Diffuse cytoplasmic + nucleolar + others 0 3 2 3 8
Diffuse cytoplasmic + others 2 8 11 22 43
Total 2 16 24 60 102
AIT = autoimmune target; anti-Rib-P = anti-ribosomal P; SLE = systemic lupus erythematosus.Arthritis Research & Therapy    Vol 11 No 3 Jearn and Kim
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colleagues’ article. We agree that anti-Rib-P, just like anti-Sm
or anti-nDNA, could be considered an effective marker
antibody in the diagnosis of SLE. We would like to insist,
however, that the improvement of the antinuclear antibody
test substrate, which is the important diagnostic tool for SLE,
is the foremost agenda to be dealt with.
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